Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers - PubMed
4 days ago
- #multiple-myeloma
- #outpatient-care
- #teclistamab
- Study explores real-world teclistamab administration in community and outpatient settings.
- Mixed-methods approach includes surveys, interviews, and roundtable discussions with hematology providers.
- 53% of practices employed outpatient step-up dosing (SUD), 26% inpatient SUD, and 21% referred out.
- Key patient requirements for outpatient SUD: caregiver support (90%), proximity to site (70%), good performance status (65%), low disease burden (30%).
- Top triggers for inpatient admission: neurotoxicity syndrome (85%), cytokine release syndrome (70%), abnormal vital signs (60%).
- 29% of practices used prophylactic tocilizumab.
- Outpatient teclistamab SUD is feasible for selected patients, improving access while reducing costs.
- Challenges include insurance coverage for preventive treatments, though recent guideline changes have helped.